Effects of Blinking Exercise on Palpebral Fissure Height and Tear Film Parameters

UMIN ID: UMIN000055608

Registered date:25/09/2024

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Dry Eye, Healthy Volunteers
• Date of first enrollment: 2023/10/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Blinking Exercise
Artifical Tears

Outcome(s)

• Primary Outcome: palpebral fissure height (mm)
• Secondary Outcome: Subjective Symptoms SPEED Score: Evaluates the frequency and severity of dry eye symptoms, scoring from 0 to 28. Visual Analog Scale (VAS): Independently rates 8 symptoms (dryness, eye fatigue, discomfort, blurred vision, foreign body sensation, pain, heaviness, difficulty opening eyes) from 0 (no symptoms) to 100 (maximum symptoms). Measurements using idra Tear lipid layer thickness (nm) Tear meniscus height (mm) Blink quality (%), complete/incomplete blinks, duration (seconds) Non-invasive tear break-up time (NIBUT first, average) (seconds) Corneal and conjunctival epithelial damage score: Assessed using fluorescein staining (0-9). Tear film break-up time with fluorescein (FBUT) (seconds): Average of 3 measurements.

Key inclusion & exclusion criteria

• Age minimum: 18years-old
• Age maximum: 59years-old
• Gender: Male and Female
• Exclude criteria: Patients with acute eye or eyelid diseases Obvious eyelid or ocular surface diseases (congenital eyelid abnormalities, entropion, ectropion, Sjogren's syndrome) Thyroid eye disease or neurological conditions (e.g., oculomotor nerve palsy, myasthenia gravis, Horner's syndrome) Use of anti-glaucoma eye drops History of eyelid surgery (e.g., ptosis correction, blepharoplasty) or facial fractures Daily use of hard contact lenses Recent eye surgery,IPL,LipiFlow, Botox within 3 months Ocular allergies during testing Judged as unsuitable by the principal investigator or co-investigator.

Related Information

• Primary Sponsor: Itoh Clinic
• Secondary Sponsor: Lid and meibomian gland working group
• Source(s) of Monetary Support: Itoh Clinic,None